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11 other countries had been included. COPD patients were recorded from a ter-
ritary care hospital in 2012. One-year costs were identified by applying cost data 
to medical information obtained by medical records. The cost analysis was based 
on cost of illness methodology. Costs included those for medications, laboratory 
and diagnostic tests, outpatient visits and hospital stays. Results: There were 612 
patients recruited. Patients were categorized by GOLD classification: 14.29% GOLDI, 
15.28% GOLDII, 38.21% GOLDIII, 32.23% GOLD IV. The median of hospitalization day 
was 9 days. 36.1% of patients were rehospitalized in 90 days. The mortality rate was 
3.1% because of exacerbation. The mean total direct costs was € 4,135.60 per patient 
in a year. The total annual cost was correlated with disease severity. Hospitalization 
contributed the major portion of cost and also correlated with disease severity. 
The average outpatient cost was € 98.62, hospitalization cost including interven-
tion was € 1,548.56, laboratory and diagnostic tests cost were € 103,03, comorbid-
ity and complication cost were € 1.493,88, medication cost with side effects were 
€ 903,59. ConClusions: There is a significant correlation between the cost of COPD 
and disease severity with hospitalization leading to disease exacerbation being a 
major contributor to cost. The keys to reducing health care costs lie beneath reducing 
the frequency of exacerbations and disease severity. As expected, the highest cost 
component was hospitalization, comorbidity and complication cost respectively.
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objeCtives: Ireland currently administers a universal BCG vaccination programme 
to infants. In order to assess the cost effectiveness of this programme, it is vital to 
have accurate cost estimates of the burden of tuberculosis (TB) illness in infants. The 
aim of the current study was to cost the diagnosis and treatment of an episode of the 
following health states; pulmonary TB, extrapulmonary TB, TB meningitis and latent 
TB, from the health care payer’s perspective. The cost of contact tracing per primary 
case of TB was also estimated. Methods: Decision trees were constructed to reflect 
typical episodes of care in the diagnosis and treatment of each health state. Resource 
use and unit cost data were applied to each node in the decision tree. The probabili-
ties of events occurring were derived from the literature and expert clinical opinion. 
Main costs included were inpatient medical/surgical costs, pediatrician outpatient 
appointments, medications, laboratory tests and x-rays. Each health state included a 
cost for a Directly Observed Therapy programme. Direct medical costs were calculated 
and the 2012 price year was used. Results: The direct medical costs of diagnosing 
and treating a case of pulmonary TB, extrapulmonary TB, TB meningitis and latent TB 
were estimated to be approximately € 8153, € 12224, € 15752 and € 894 respectively. The 
main drivers in the costs are the length of hospital stay and the number of pediatri-
cian visits. The cost of contact tracing per primary case of TB was estimated to be 
approximately € 4,248, which was based on a mean number of 9.4 contacts examined 
per primary TB case. ConClusions: To our knowledge this is the first investigation 
of costs associated with paediatric TB within the context of the Irish health care 
setting and will allow for a more robust estimation of the cost effectiveness of BCG 
vaccination programmes, which will benefit the health care payer.
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objeCtives: Comparative pharmacoeconomic assessment of COPD therapy of 
patients in GOLD 2-3 stages in Moscow health care system. Methods: Retrospective 
analysis of 130 cases during 1 year routine practice of patients with COPD in Moscow 
outpatients departments. Basic therapy strategies were obtaned: 1) monotherapy with 
indacaterol (14 pts. Low # of pts is because of the product was launched less than 
year ago); 2) monotherapy by tiotropium (33 pts), 3) fixed combination LABA + ICS 
(38 pts); 4) tiotropium plus fixed combination of LABA and ICS (45 pts). Cost of illness 
via calculation of direct medical costs on diagnostic, hospitalization, treatment of 
main disease and complications based on Federal Standards of COPD treatment and 
regional tariffs on cervices was estimated. Data on prices on medical products were 
obtained from State Register of medical products and www.aptechka.ru. Results: 
The most expencive strategy is management of group 4 - 86.5 KRUR/pt/year (1 Euro 
- 40 RUR) where 67% are costs on base drugs and 31% are hospitalization expenses. 
Usage of fixed combinations LABA + ICS is comparable with monotherapy by tiotro-
pium, total costs are 47 and 49 KRUR/pt/year accordingly. But if the reason of main part 
of the costs in group 3 is hospitalization due to exacerbation - 69%, for group 2 - 61% 
are expenditures on tiotropium. The most preferable is treatment of group 1 - 32847 
RUR/pt/year, where 55% - part on indacaterol, 42% - hospital treatment, 3% - urgent 
care. ConClusions: In spite of high price, indacaterol is the most economic prefer-
able product for basic COPD treatment of patients in GOLD 2-3 stages
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objeCtives: To predict health care costs in asthma using the EQ-5D health-related 
quality-of-life (HRQoL) index score. Methods: We extracted data from the 2000-
03 Medical Expenditure Panel Survey (MEPS) on adult respondents who had EQ-5D 
index scores. Asthma patients were identified using ICD-9 (= 493) and self-report on 
disease (n= 3,783). To account for non-random selection of positive spending, the 
chronic disease with a greater use of pain medications was RA/OA (44.8% vs 41.2%, 
P< 0.0001). COPD patients had more chronic use of short-acting opioids (24.2% vs. 
15.1%, P< 0.0001) and long-acting opioids (4.4% vs. 1.9%, P< 0.0001). Among COPD 
patients, those with chronic pain had higher mean annual direct cost [$24,261 vs. 
$10,390 (p< 0.0001)] which was largely attributable to increased hospitalizations 
(42.7% vs 25.4%, p< 0.0001). By comparison, the mean total medical cost for the 
matched cohort was $17,681 for those with chronic pain compared to $6,543 for 
individuals without chronic pain (P< 0.0001). Pain-related utilization was approxi-
mately 20% of COPD patients’ annual direct cost. ConClusions: COPD patients 
have increased prevalence of and utilization for chronic pain as compared to all 
other chronic illnesses except RA/OA. Individuals with chronic disease and chronic 
pain have more than double the cost of those without chronic pain, and this differ-
ence is even higher among individuals with COPD.
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objeCtives: To describe the direct costs to society of COPD per severity grades 
using the “Echantillon Generaliste de Beneficiaires”(EGB). EGB is a database 
which contains all health care resources used by a random 1/97 permanent sam-
ple of the French population covered by the national health care insurance sys-
tem. Methods: Several algorithms were developed to identify patients with COPD 
and to distinguish patients between four severity grades (1-4) based on health care 
consumption. These algorithms were based on age, rate and history of hospitaliza-
tions, treatments and tests received by the individuals. Exacerbations as well as their 
severity were identified through both antibiotics/corticosteroids drugs prescribed 
and hospitalizations. Total health care costs were calculated and a case-control 
approach was then used to estimate the cost of COPD. Exacerbations costs were 
calculated through a linear regression analysis including age and gender. Results: 
Based on the 10,715 COPD patients identified in the EGB, its prevalence was esti-
mated to 4.2% of the population beyond 40 years. The mean annual overall direct 
health care cost in this population was estimated to be € 9,382. Annual average costs 
were € 7,628; 10,770, 14,979 and 20,747 for severity grade 1-4 (severity data-base 
defined) respectively. The yearly cost of COPD itself was 5,516€ : 45.5% related to 
hospital care and 20.0% to pharmaceuticals (6.0% to long-acting bronchodilators). 
The average exacerbation cost was € 1,664 (SD: € 86.6). The global economic burden of 
COPD in France was therefore estimated over € 7 billions (4% of the national health 
care expense). ConClusions: Our study provides new solutions to estimate the 
burden of COPD in France using existing national databases. It confirms that COPD 
is associated with significant economic burden and the striking direct relationship 
between the cost of care and severity of the disease.
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objeCtives: Chronic Obstructive Pulmonary Disease (COPD) is a highly prevalent 
chronic inflammatory disease. Some COPD patients show a co-diagnosis of asthma 
(COPD-A). This real-life observational study assessed the frequency of exacerbations, 
the use of health care resources and their associated costs in patients with COPD only 
and COPD-A. Methods: Medical records from 6 Primary Care (PC) and one general 
hospital were reviewed and data from 2011 were collected from COPD and COPD-A 
patients aged 40 year or older who met specific inclusion/exclusion criteria. Main 
study variables were demography, co-morbidities, exacerbations and resources utili-
zation. Results: A total of 1210 COPD and 102 COPD-A, mean age (% male) 71.8 (85.5) 
and 71.2 (65.7) years, respectively, were included. Mean co-morbidity burden was simi-
lar in both groups with 7.9 and 7.8 diseases per patient. Most frequent co-morbidities 
(% in COPD; % in COPD-A) were dyslipidemia (63.0; 60.8) and arterial hypertension 
(59.5; 62.7) whereas the proportion of exacerbations (%) were 35.0 and 42.2, respec-
tively. Mean number of exacerbations per patient per year was 1.2 in COPD and 1.6 in 
COPD-A. The frequency of severe exacerbations (%) requiring hospitalizations was 
0.4 and 0.7, while those requiring oral corticosteroids was 24.4 and 33.0, respectively. 
Mean per patient, per year health care resources costs (Euro) were 2152.2 and 2207.5 
for PC-associated costs, and 1361.6 and 1754.3 for specialist care-associated costs, 
respectively. ConClusions: Exacerbations are frequent complications in COPD and 
COPD-A patients. Both groups show high proportion of co-morbidities and use of 
health care resources which were higher in the COPD-A group. Health care-related 
costs are high and are mainly related to hospitalizations and drug therapy.
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objeCtives: COPD has a major burden on Turkey’s health care system. It leads 
to high mortality, morbidity and frequent use of health care resources. This study 
determined the total direct health care costs for the management of COPD patients 
with differing degrees of disease severity. The study also aimed to find the key cost 
drivers in the management of COPD in Turkey. Methods: The methodology was 
based on a study conducted by European Respiratory Society in which Turkey and 
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objeCtives: According to the GOLD-2011 report pharmacotherapy in stable COPD 
is used to reduce the symptoms, frequency and severity of exacerbations, improve 
health status and exercise tolerance. Methods: Our aim was to assess the list of 
medicines, which are available in Ukraine for COPD treatment. We compared the 
medications included in the State Formulary of Ukraine with the dosage forms and 
typical doses of COPD medications list provided by GOLD-2011. Also we calculated 
annual course costs for each drug in different dosage forms. The annual course was 
considered as amount of medicine for 365 days in appropriate for COPD basis dosing. 
Information about the medicine prices was obtained from the ukrainian electronic 
pricing database “MORION”. The EUR/UAH exchange rate was 1 EUR = 10.53 UAH 
(20.06.2013) Results: The State Formulary of Ukraine (SFU) contains 19 medicines 
for INN provided by GOLD-2011: 5 INN are in metered dose inhalers (MDI), 5 - in 
dry powder inhalers (DPI), 1 - in smart mist inhaler (SMI), 5 solutions for nebulizer 
and 3 - in tablets. Salbutamol, salmeterol, indacaterol, fluticasone, beclomethasone 
in DPI are not included in the list of SFU, formoterol in MDI and aminophylline, 
prednisone in tablets are not included in this list as well. The most expensive drug 
is tiotropium with annual costs 604.46 EUR for SMI and 533.81 EUR for DPI. The 
annual costs of salmeterol in MDI and formoterol in DPI are 318.55 and 277.30, 
respectively. The cheapest medicine is salbutamol in MDI with 22.13 EUR annually 
but annual costs of salbutamol solution for nebulizer amount 464.48 EUR per year 
per patient. ConClusions: The State Formulary of Ukraine should be reached by 
medicines for COPD management recommended by GOLD. Annual COPD basis costs 
are depending not only from kind of medicine but from it dosage forms as well.
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objeCtives: Inhaled corticosteroids in fixed combination with long-acting B2-
agonists could prevent and reduce chronic obstructive pulmonary disease (COPD) 
exacerbations. The aim of this analysis is to compare clinical consequences and direct 
health care costs related to treatment with budesonide/formoterol and fluticasone/
salmeterol for COPD considering the Italian National Health Service (INHS) perspec-
tive. Methods: Effectiveness data by the PATHOS study, a population-based, retro-
spective, observational registry study conducted in Sweden, in terms of reduction in 
COPD hospitalizations and COPD-related emergency departments (ED) visits were 
considered in order to estimate the differences in resource consumption between 
patients treated with budesonide/formoterol versus fluticasone/salmeterol. Base case 
considers the dosages of the 2 drugs from the PATHOS study, the cost of drugs in 
charge to INHS, COPD hospitalizations costs from Italian real world data and Italian 
national tariffs for COPD-related ED visits. Results: The real world study PATHOS 
demonstrated a significant reduction in COPD hospitalizations and COPD-related ED 
visits with budesonide/formoterol versus fluticasone/salmeterol (-29.1% and -21%, 
respectively); average dosages reported were 568 mcg/day for budesonide/formoterol 
(as budesonide dosage) and 783 mcg/day for fluticasone/salmeterol (as fluticasone 
dosage). In the base case, the treatment for 1 year of 100 patients with budesonide/
formoterol lead to a saving of 43.892€ (21.859€ for drugs, 21.864€ for COPD hospitaliza-
tions and 169€ for COPD-related ED visits) corresponding to -25.2% compared with 
fluticasone/salmeterol treatment. In the most conservative sensitivity analysis which 
consider the DDD dosages for the 2 drugs and COPD hospitalizations and COPD-
related ED visits costs from national tariffs, the treatment for 1 year of 100 patients 
with budesonide/formoterol lead to a saving of 15.523€ (5.754€ for drugs, 9.600€ for 
COPD hospitalizations and 169€ for COPD-related ED visits) corresponding to -12.5% 
compared with fluticasone/salmeterol treatment. ConClusions: Treatment with 
budesonide/formoterol compared to fluticasone/salmeterol could lead to a reduction 
in direct health care costs with relevant improvement in clinical outcomes.
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objeCtives: To re-evaluate the economic consequences of parenteral glutamine 
supplementation (PGS) in light of the recent metaanalysis confirming that PGS at a 
dose > 0,20 g/kg body weight per day in intensive care unit (ICU) patients is associ-
ated with reduced mortality, infection rate (IR) and length of stay (LOS). Methods: 
A simulation model was updated with the new meta-analysis data and clinical 
inputs for the control group from Italian ICU population reported in “Progetto 
Margherita”. Costs are evaluated from the perspective of the Italian hospital and 
derive from official sources. Sensitivity analyses are undertaken to test results’ 
reliability Results: PGS is predicted to reduce mortality rates (-29.0%), IR (-21.2%) 
and overall LOS (-1.07 days/patient), yielding a saving of € 1,047 per patient treated. 
Treatment costs are completely offset by the reduction in hospital stay costs and 
antibiotic costs. Probabilistic sensitivity analysis indicates PGS strategy as dominant 
in more than 90% of cases. ConClusions: Also with contemporary comparative 
efficacy data is PGS in ICU patients expected to be effective in improving outcomes 
and containing costs in Italian hospitals providing intensive care.
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objeCtives: To estimate the cost-effectiveness of a novel LAMA, glycopyrronium 
(Seebri® Breezhaler), compared with tiotropium (Spiriva®) in COPD patients from a 
Swedish societal perspective. Methods: A probabilistic Markov model was utilized to 
Heckman two-step selection model was used. The EQ-5D index score was categorized 
into categories with 0.1 gradations. Marginal effects (ME) were estimated to quantify 
the marginal changes in costs corresponding to, for instance, 0.1 increments in the 
EQ-5D index score, or the presence of asthma or asthma treatment. All costs were 
adjusted to 2003 dollars. Results: The EQ-5D index score was a significant predic-
tor of health care costs in all models, as were asthma, asthma treatment and other 
covariates (p< 0.01). The Heckman model suggested a significant positive spending 
bias (p< 0.01). For the 3 groups considered--non-asthma, asthma and asthma with 
treatment--the mean EQ-5D index scores were 0.848, 0.755 and 0.706, respectively. 
The actual mean costs were $2,355, $4,284 and $5,577, respectively. The predicted 
mean costs using Heckman model were $2,673, $4,431 and $5,618, respectively. On 
average, a 0.1 unit improvement in EQ-5D score was associated with $502 cost reduc-
tion in asthma and $693 cost reduction if asthma patients had treatment (p< 0.01). 
However, after adjusting for positive spending bias, the cost reduction was $891 and 
$961 (p< 0.01) for these two groups respectively. Greater cost reductions were associ-
ated with improving EQ-5D scores at the lower end (< 0 to 0.3) and the mid-range (0.5 
to 0.7). ConClusions: HRQoL is an important component of health care resource 
utilization. The findings suggest a significant relationship exists between health care 
costs and HRQoL data. The EQ-5D significantly predicts costs in asthma and asthma 
treatment, especially after adjusting non-random positive health care spending.
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objeCtives: Chronic-Obstructive-Pulmonary-Disease (COPD) is a prevalent health 
condition mainly associated with smoking habit, which is considered the reason 
for higher health care resources utilization and related costs in the National health 
System. The aim of this study was to analyze and compare health care resource utili-
zation and costs according to smoking status in patients with COPD in clinical practice 
in Spain. Methods: A retrospective cohort nested case-control study was designed. 
Cases were current smokers, while two controls (former smokers) per case matched 
for age, sex, duration of COPD, and burden of comorbidity (number of diagnosis and 
Charlson index) were included using data from medical records. Non-institutionalized 
COPD, both genders, 40 years of age and older, seen consecutively over a period of 4 
years before the index date and fulfilling eligibility criteria were considered eligible for 
analysis. Analysis used regression and general linear models with covariates to com-
pare direct and indirect costs and resource utilization. Results: A total of 930 COPD 
medical records were analyzed: 310 corresponding to cases (current smokers) and 630 
to controls (former smokers). Mean age was 69.4 years (84.6% male). COPD was more 
severe in cases; Odds ratio (OR)= 1.7 (95% CI 1.1;2.1), and higher percentage of current 
smokers had exacerbations [OR= 2,7 (2.0;3.8)], with 4.2 vs. 1.7 exacerbations per year, 
respectively, on average (p< 0.001). Smokers used more physicians visits both at pri-
mary care and specialized level, and emergency room as well. Drugs-based therapies 
were more common in current smokers COPD subjects. As a consequence, smokers 
had higher average annual health care costs; € 3,784 (1,888) vs. € 2,302 (2,451) in former 
smokers (p< 0.001). ConClusions: COPD smoker patients had more exacerbations 
and higher severity of disease. Also, used more health care resources, particularly 
physicians visits and drugs-based therapies resulting in higher health care costs to 
the national health System.
PRS29
coStS and effectiveneSS of non-Smoking clinic
Laine J.
Pfizer Oy, Helsinki, Finland
objeCtives: In Finland a new Tobacco Act entered into force in October 2010 with 
the aim of limiting marketing and supply of tobacco products. The long-term objec-
tive of the Finnish government is to make Finland tobacco-free by 2040. Several 
work places and organizations have declared themselves non-smoking. The city 
of Mikkeli with a population of 55 000, has declared itself a non-smoking city and 
has established a non-smoking clinic in September 2011. Citizens contacting public 
health care and willing to quit smoking will be referred to the clinic. Methods: 
Cross-sectional data was gathered 12 months after the establishment of the clinic. 
Costs related to investment and clinic’s resource utilization were estimated. A health 
care perspective was applied. Results: We studied 74 citizens, who had a least one 
visit during the first year since the establishment of the clinic. Of them 37% man-
aged to quit smoking. Investment costs related to planning and training of nurses 
were 168€ per quitter. Operational costs were 141-167€ per quitter. Total costs per 
quitter were 309-335€ . In the future investment costs per customer will decrease 
as investment costs were nonrecurring. ConClusions: Our results were slightly 
better than what was achieved in an occupational health care non-smoking project 
in Finland (37% vs. 31%). In 2010 the average total costs of occupational health care 
were 340€ per employee in Finland. This is almost the same as the costs per quitter 
in this study. Cost of cigarettes is about 1800€ per average smoker in Finland. Health 
care costs related to lung cancer and stroke are about 18500€ per case during the 
first year. Pharmacological treatment costs about 200-400€ to quitter in average. 
Investing in smoking clinic is justified from economic and effectiveness point of 
views. The non-smoking clinic is still in operation.
PRS30
the liSt of medicineS foR coPd tReatment in State foRmulaRy of 
ukRaine and Related coStS
Tolubaiev V., Zalis’ka O., Kacheray Y.
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
